Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Amortization of Deferred Charges (2019)

VYNE Therapeutics (VYNE) has disclosed Amortization of Deferred Charges for 1 consecutive years, with $160000.0 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Amortization of Deferred Charges changed N/A year-over-year to $160000.0, compared with a TTM value of $644000.0 through Dec 2019, changed N/A, and an annual FY2019 reading of $644000.0, changed N/A over the prior year.
  • Amortization of Deferred Charges was $160000.0 for Q4 2019 at VYNE Therapeutics, up from $155000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $177000.0 in Q1 2019 and bottomed at $152000.0 in Q2 2019.